Recombinant Human Factor VII Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1965
Recombinant Human Factor VII Protein (His Tag)

Recombinant Human Factor VII Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1965
Catalog No.: BLPSN-1965

Product Overview

Tag His
Host Species Human
Accession P08709
Synonym Coagulation factor 7, Coagulation factor VII, SPCA
Background Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.
Description A DNA sequence encoding the human F7 isoform B (P08709-2) (Met 1-Pro 444) was expressed, fused with a His tag at the C-terminus.
Source HEK293
Predicted N Terminal Ala 39
AA Sequence Met 1-Pro 444
Molecular Weight The secreted mature form of recombinant human F7 consists of 417 a.a. and predictes a molecular mass of 46.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh F7 is approximately 50 kDa.
Purity >95% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Recently viewed